B³ Pharma is validating its Angiopep platform through ANG1005, a peptide-drug conjugate that leverages the LRP-1 receptor to cross the blood-brain barrier and target lethal brain metastases. Preclinical and clinical studies have demonstrated its safety and efficacy, paving the way for a pivotal Phase III trial in patients with high unmet medical needs.
Click on each block to download the detailed slide and learn more about our clinical trials.
ANG1005 combines Angiopep-2 and Paclitaxel with succinyl linkers, demonstrating its ability to bind the LRP-1 receptor and cross the BBB. Covered by patents until 2036, it establishes the foundation for B³ Pharma’s pipeline.
ANG1005 has shown strong clinical results, addressing unmet needs in oncology by enabling paclitaxel to effectively reach tumor cells in the brain. Published data confirm its ability to penetrate LRP-1 expressing tissues, providing proof of clinical relevance for the platform.
Scheduled to begin in Q2 2026, this will be the first randomized trial for breast cancer brain metastases and leptomeningeal carcinomatosis under FDA Special Protocol Agreement. Focusing on HER2- patients, the trial will evaluate overall survival as the primary endpoint, with an adaptive design to optimize efficiency and reduce risk.
B³ Pharma is advancing ANG1005, its lead Angiopep-based conjugate, through a rigorous clinical program. From demonstrating its ability to cross the blood-brain barrier, to validating efficacy in patients, and now preparing for a pivotal Phase III trial, each milestone confirms the potential of the platform to transform brain metastases treatment.
